ID: ALA2448165

Max Phase: Preclinical

Molecular Formula: C16H20ClN3O2

Molecular Weight: 321.81

Molecule Type: Small molecule

Representations

Canonical SMILES:  COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1C2CC3CN(C2)CC31

Standard InChI:  InChI=1S/C16H20ClN3O2/c1-22-14-4-13(18)12(17)3-10(14)16(21)19-15-9-2-8-5-20(6-9)7-11(8)15/h3-4,8-9,11,15H,2,5-7,18H2,1H3,(H,19,21)/t8?,9?,11?,15-/m1/s1

Standard InChI Key:  MRKYTIJPEALHEE-YFCKSMKJSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 321.81

Molecular Weight (Monoisotopic): 321.1244

AlogP: 1.61

#Rotatable Bonds: 3

Polar Surface Area: 67.59

Molecular Species: BASE

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 9.79

CX LogP: 0.63

CX LogD: -1.72

Aromatic Rings: 1

Heavy Atoms: 22

QED Weighted: 0.83

Np Likeness Score: -0.17

References

1. Flynn DL, Becker DP, Spangler DP, Nosal R, Gullikson GW, Moummi C, Yang D.  (1992)  New aza(nor)adamantanes are agonists at the newly identified serotonin 5-HT4 receptor and antagonists at the 5-HT3 receptor,  2  (12): [10.1016/S0960-894X(00)80441-2]

2. Becker DP, Flynn DL, Villamil CI..  (2004)  Bridgehead-methyl analog of SC-53116 as a 5-HT4 agonist.,  14  (12): [PMID:15149647] [10.1016/j.bmcl.2004.04.021]

3. Becker DP, Flynn DL, Shone RL, Gullikson G..  (2004)  Azaadamantane benzamide 5-HT4 agonists: gastrointestinal prokinetic SC-54750.,  14  (22): [PMID:15482914] [10.1016/j.bmcl.2004.09.005]

4. Becker DP, Flynn DL, Moormann AE, Nosal R, Villamil CI, Loeffler R, Gullikson GW, Moummi C, Yang DC..  (2006)  Pyrrolizidine esters and amides as 5-HT4 receptor agonists and antagonists.,  49  (3): [PMID:16451077] [10.1021/jm0509501]

Source

Source(1):

• Scientific Literature